Antithrombotic medication for cardioembolic stroke prevention.

摘要: Embolism of cardiac origin accounts for about 20% ischemic strokes. Nonvalvular atrial fibrillation is the most frequent cause cardioembolic stroke. Approximately 1% population affected by fibrillation, and its prevalence growing with ageing in modern world. Strokes due to cardioembolism are general severe prone early recurrence have a higher long-term risk mortality. Despite enormous preventive potential, continuous oral anticoagulation prescribed less than half patients who factors no contraindications anticoagulation. Available evidence does not support routine immediate acute Anticoagulation therapy's associated hemorrhage monitoring requirements encouraged investigation alternative therapies individuals fibrillation. New anticoagulants being tested prevention stroke low-molecular-weight heparins (LMWH), unfractionated heparin, factor Xa inhibitors, or direct thrombin inhibitors like dabigatran etexilate rivaroxaban. The later exhibit stable pharmacokinetics obviating need coagulation dose titration, they lack clinically significant food drug interaction. Moreover, offer another potential that includes fixed dosing, administration, rapid onset action. There several concerns regarding harm, including an increased hepatotoxicity, bleeding, coronary events. Therefore, additional trials postmarketing surveillance will be needed.